After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...

Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that ...

2seventy bio (NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of ...

ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, which are currently in progress, are comparing the safety and efficacy of icotrokinra to both placebo and Sotyktu (deucravacitinib). The dual primary endpoints ...

Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.

In the POETYK PsA-2 trial, 54.2% of Sotyktu-treated patients achieved ACR20 at Week 16 vs. 39.4% on placebo. Sotyktu improved PsA disease activity, including clinical signs, extra-articular ...

Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to Bristol-Myers Squibb & Co’s BMY Sotyktu deucravacitinib in patients with moderate-to-severe ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...